Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Mediport use as an acceptable standard for CAR T cell infusion.

Autor: Eylon M; College of Medicine, Central Michigan University, Mount Pleasant, MI, United States., Prabhu S; Department of Pediatrics, Division of Hematology and Oncology, Stanford University School of Medicine, Palo Alto, CA, United States., John S; Department of Pediatrics, The University of Texas Southwestern Medical Center/Children's Health, Dallas, TX, United States., King MJM; College of Medicine, Central Michigan University, Mount Pleasant, MI, United States., Bhatt D; Department for Biology, Stanford University, Palo Alto, CA, United States., Curran KJ; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, United States., Erickson C; Department of Pediatrics, Division of Hematology and Oncology, Stanford University School of Medicine, Palo Alto, CA, United States., Karras NA; Department of Pediatrics, City of Hope National Medical Center, Duarte, CA, United States., Phillips CL; Department of Pediatrics, University of Cincinnati, Cincinnati, OH, United States.; Cincinnati Children's Hospital Medical Center, Cancer and Blood Disease Institute, Cincinnati, OH, United States., Satwani P; Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Pediatrics, Columbia University Medical Center, New York, NY, United States., Hermiston M; University of California, San Francisco Benioff Children's Hospital, San Francisco, CA, United States., Southworth E; University of California, San Francisco Benioff Children's Hospital, San Francisco, CA, United States., Baumeister SHC; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Dana Farber/Boston Children's Hospital, Boston, MA, United States., Talano JA; Department of Pediatric Hematology Oncology, Medical College of Wisconsin, Milwaukee, WI, United States., MacMillan ML; Department of Pediatrics, Division of Pediatric Blood and Marrow Transplantation, University of Minnesota Medical School, Minneapolis, MN, United States., Rossoff J; Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, United States., Bonifant CL; Sidney Kimmel Comprehensive Cancer Center, Division of Pediatric Oncology, Philadelphia, MD, United States., Myers GD; Children's Mercy Hospital, University of Missouri, Columbia, MO, United States., Rouce RH; Bone Marrow Transplant/Stem Cell Transplant Program, Texas Children's Cancer Center, Houston, TX, United States., Toner K; Division of Blood and Marrow Transplant and CAR-T Program, Children's National Hospital, Northwest, DC, United States., Driscoll TA; Pediatric Transplant and Cellular Therapy, Duke Children's Hospital & Health Center, Durham, NC, United States., Katsanis E; Department of Pediatrics, University of Arizona, AZ, United States., Salzberg DB; Center for Cancer and Blood Disorder, Phoenix Children's Hospital, Phoenix, AZ, United States., Schiff D; Division of Hematology/Oncology, Rady Children's Hospital, San Diego, CA, United States., De Oliveira SN; Department of Pediatrics, University of California Los Angeles (UCLA) Mattel Children's Hospital, Los Angeles, CA, United States., Capitini CM; Department of Pediatrics and Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States., Pacenta HL; Cook Children's Hematology and Oncology, Cook Children's Hospital, Fort Worth, TX, United States.; Department of Pediatrics, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, United States., Pfeiffer T; Saint Louis Children's Hospital One Children's Pl, Saint Louis, MO, United States., Shah NC; Yale Medicine, Yale University and Yale New Haven Children's Hospital New Haven, New Haven, CT, United States., Huynh V; Pediatric Oncology, CHOC Children's Hospital of Orange County, Orange County, CA, United States., Skiles JL; Riley Children Health, Indiana University Health, IN, United States., Fraint E; Division of Pediatric Hematology, Oncology, and Cellular Therapy, The Children's Hospital at Montefiore, Bronx, NY, United States., McNerney KO; Department of Pediatrics, John Hopkins All Children's Hospital, St. Petersburg, FL, United States., Quigg TC; Section of Pediatric BMT and Cellular Therapy, Helen DeVos Children's Hospital, Grand Rapids, MI, United States., Krueger J; Division of Hematology/Oncology, The Hospital For Sick Children, Toronto, ON, Canada., Ligon JA; Health Pediatric Blood & Marrow Transplant and Cellular Therapy, University of Florida, Gainesville, FL, United States., Fabrizio VA; Colorado Children's Hospital, University of Colorado, Boulder, CO, United States., Baggott C; Department of Pediatrics, Division of Hematology and Oncology, Stanford University School of Medicine, Palo Alto, CA, United States., Laetsch TW; Department of Pediatrics, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, United States., Schultz LM; Department of Pediatrics, Division of Hematology and Oncology, Stanford University School of Medicine, Palo Alto, CA, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Oct 27; Vol. 14, pp. 1239132. Date of Electronic Publication: 2023 Oct 27 (Print Publication: 2023).

HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL.

Autor: McNerney KO; Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, FL.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD., Si Lim SJ; Division of Oncology, Department of Pediatrics, John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI., Ishikawa K; Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI., Dreyzin A; Center for Cancer and Blood Disorders, Children's National Hospital, Washington, DC., Vatsayan A; Center for Cancer and Blood Disorders, Children's National Hospital, Washington, DC., Chen JJ; Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawai'i at Manoa, Honolulu, HI., Baggott C; Department of Pediatrics, School of Medicine, Stanford University, Stanford, CA., Prabhu S; Center for Cancer Cell Therapy, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA., Pacenta HL; Department of Pediatrics, University of Texas Southwestern Medical Center/Children's Health, Dallas, TX.; Division of Hematology and Oncology, Cook Children's Medical Center, Fort Worth, TX., Philips C; Division of Pediatrics, University of Cincinnati, Cincinnati, OH.; Cincinnati Children's Hospital Medical Center, Cancer and Blood Disease Institute, Cincinnati, OH., Rossoff J; Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL., Stefanski HE; National Marrow Donor Program/Be the Match, Minneapolis, MN., Talano JA; Division of Hematology/Oncology/Blood and Marrow Transplantation, Department of Pediatrics, Medical College of Wisconsin and Children's Wisconsin, Milwaukee, WI., Moskop A; Division of Hematology/Oncology/Blood and Marrow Transplantation, Department of Pediatrics, Medical College of Wisconsin and Children's Wisconsin, Milwaukee, WI., Verneris M; University of Colorado School of Medicine, Children's Hospital of Colorado, Aurora, CO., Myers D; Department of Hematology, Oncology and Blood and Marrow Transplantation, Children's Mercy Hospital, University of Missouri Kansas City, Kansas City, MO., Karras NA; Department of Pediatrics, City of Hope National Medical Center, Duarte, CA., Brown P; Department of Oncology, Sidney Kimmel Cancer Center, John Hopkins University School of Medicine, Baltimore, MD., Bonifant CL; Department of Oncology, Sidney Kimmel Cancer Center, John Hopkins University School of Medicine, Baltimore, MD., Qayed M; Division of Pediatric Hematology/Oncology and Bone Marrow Transplantation, Aflac Cancer and Blood Disorders Center, Emory University and Children's Healthcare of Atlanta, Atlanta, GA., Hermiston M; University of California San Francisco Benioff Children's Hospital, San Francisco, CA., Satwani P; Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Pediatrics, Columbia University Medical Center, New York, NY., Krupski C; Division of Pediatrics, University of Cincinnati, Cincinnati, OH.; Cincinnati Children's Hospital Medical Center, Cancer and Blood Disease Institute, Cincinnati, OH., Keating AK; University of Colorado School of Medicine, Children's Hospital of Colorado, Aurora, CO., Baumeister SHC; Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, MA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Pediatrics, Harvard Medical School, Boston, MA., Fabrizio VA; University of Colorado School of Medicine, Children's Hospital of Colorado, Aurora, CO., Chinnabhandar V; Division of Pediatric Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN., Egeler E; Center for Cancer Cell Therapy, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA., Mavroukakis S; Center for Cancer Cell Therapy, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA., Curran KJ; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.; Department of Pediatrics, Weill Cornell Medical College, Cornell University, New York, NY., Mackall CL; Department of Pediatrics, School of Medicine, Stanford University, Stanford, CA.; Center for Cancer Cell Therapy, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, CA.; Department of Medicine, School of Medicine, Stanford University, Stanford, CA., Laetsch TW; Department of Pediatrics and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.; Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA., Schultz LM; Department of Pediatrics, School of Medicine, Stanford University, Stanford, CA.

Publikováno v: Blood advances [Blood Adv] 2023 Jun 27; Vol. 7 (12), pp. 2758-2771.

Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.

Autor: Schultz LM; Division of Hematology and Oncology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA., Eaton A; Division of Pediatric Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN., Baggott C; Stanford University School of Medicine, Stanford Cancer Institute, Palo Alto, CA., Rossoff J; Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL., Prabhu S; Stanford University School of Medicine, Stanford Cancer Institute, Palo Alto, CA., Keating AK; University of Colorado School of Medicine, Children's Hospital of Colorado, Aurora, CO., Krupski C; Department of Pediatrics, University of Cincinnati, Cincinnati, OH.; Cincinnati Children's Hospital Medical Center, Cancer and Blood Disease Institute, Cincinnati, OH., Pacenta H; Department of Pediatrics, The University of Texas Southwestern Medical Center/Children's Health, Dallas, TX.; Division of Hematology and Oncology, Cook Children's Medical Center, Fort Worth, TX., Philips CL; Department of Pediatrics, University of Cincinnati, Cincinnati, OH.; Cincinnati Children's Hospital Medical Center, Cancer and Blood Disease Institute, Cincinnati, OH., Talano JA; Division of Hematology/Oncology/Blood and Marrow Transplantation, Department of Pediatrics, Medical College of Wisconsin and Children's Wisconsin, Milwaukee, WI., Moskop A; Division of Hematology/Oncology/Blood and Marrow Transplantation, Department of Pediatrics, Medical College of Wisconsin and Children's Wisconsin, Milwaukee, WI., Baumeister SHC; Pediatric Hematology-Oncology, Harvard Medical School, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA., Myers GD; Children's Mercy Hospital, University of Missouri Kansas City, Kansas City, MO., Karras NA; Department of Pediatrics, City of Hope National Medical Center, Duarte, CA., Brown PA; Department of Oncology, Sidney Kimmel Cancer Center at John Hopkins School of Medicine, Baltimore, MD., Qayed M; Emory University and Children's Healthcare of Atlanta, Druid Hills, GA., Hermiston M; University of California San Francisco Benioff Children's Hospital, San Francisco, CA., Satwani P; Division of Pediatric Hematology, Oncology and Stem Cell Transplant, Department of Pediatrics, Columbia University Medical Center, New York, NY., Wilcox R; Children's Mercy Hospital, University of Missouri Kansas City, Kansas City, MO., Rabik CA; Division of Hematologic Malignancies I, Center for Drug Evaluation and Research (CDER), FDA., Fabrizio VA; University of Colorado School of Medicine, Children's Hospital of Colorado, Aurora, CO.; Department of Pediatrics, Memorial Sloan Kettering Cancer Center.; Department of Pediatrics, Weill Cornell Medical College., Chinnabhandar V; Division of Pediatric Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN., Kunicki M; Stanford University School of Medicine, Stanford Cancer Institute, Palo Alto, CA., Mavroukakis S; Stanford University School of Medicine, Stanford Cancer Institute, Palo Alto, CA., Egeler E; Stanford University School of Medicine, Stanford Cancer Institute, Palo Alto, CA., Li Y; Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.; Department of Pediatrics and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.; Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA., Mackall CL; Stanford University School of Medicine, Stanford Cancer Institute, Palo Alto, CA.; Division of Hematology and Oncology, Department of Pediatrics, Stanford University School of Medicine, Center for Cancer Cell Therapy, Stanford Cancer Institute, Palo Alto, CA.; Division of Blood and Bone Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Center for Cancer Cell Therapy, Stanford Cancer Institute, Palo Alto, CA., Curran KJ; Department of Pediatrics, Memorial Sloan Kettering Cancer Center.; Department of Pediatrics, Weill Cornell Medical College., Verneris MR; University of Colorado School of Medicine, Children's Hospital of Colorado, Aurora, CO., Laetsch TW; Department of Pediatrics, The University of Texas Southwestern Medical Center/Children's Health, Dallas, TX.; Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.; Department of Pediatrics and Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.; Division of Oncology, Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA., Stefanski H; Division of Pediatric Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Jan 10; Vol. 41 (2), pp. 354-363. Date of Electronic Publication: 2022 Sep 15.

Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.

Autor: Driouk L; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, United States., Gicobi JK; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, United States., Kamihara Y; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, United States., Rutherford K; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, United States., Dranoff G; Novartis Institutes of Biomedical Research, Cambridge, MA, United States., Ritz J; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Baumeister SHC; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.; Division of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Division of Pediatric Hematology-Oncology, Boston Children's Hospital, Boston, MA, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2020 Dec 15; Vol. 11, pp. 580328. Date of Electronic Publication: 2020 Dec 15 (Print Publication: 2020).